Guided Therapeutics, Inc. Passes Annual ISO Quality Audit Necessary for Continued CE Mark Certification
Published: Feb 14, 2013
NORCROSS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP) today announced that it passed its annual independent quality audit and, with all external and mechanical testing completed, plans to apply the Edition 3 CE Mark to the LuViva® Advanced Cervical Scan for expanded commercial introduction of the product in select European countries. “Passing the annual ISO audit and completing all the testing required to apply the Edition 3 CE Mark to LuViva® are major accomplishments for the company and allows management to accelerate its planned product rollout, in tandem with our production ramp up,” said Mark L. Faupel, Ph.D., CEO and president of Guided Therapeutics, Inc.